Online inquiry

IVTScrip™ mRNA-Human ARHGEF19, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK23212MR)

This product GTTS-WK23212MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARHGEF19 protein. This product can be used in Mitotic arrest phase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_153213.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 128272
UniProt ID Q8IW93
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARHGEF19, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK23212MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK28288MR IVTScrip™ mRNA-Human ARHGAP23, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARHGAP23
GTTS-WK20604MR IVTScrip™ mRNA-Human ANKRD18A, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ANKRD18A
GTTS-WK10106MR IVTScrip™ mRNA-Human ADAMTS7, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADAMTS7
GTTS-WK19737MR IVTScrip™ mRNA-Human ANKRD9, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD9
GTTS-WK25879MR IVTScrip™ mRNA-Human ARGLU1, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARGLU1
GTTS-WK28110MR IVTScrip™ mRNA-Human ASGR1, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ASGR1
GTTS-WK20837MR IVTScrip™ mRNA-Human alpha-SMA, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA alpha-SMA
GTTS-WK27831MR IVTScrip™ mRNA-Human ASXL1, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ASXL1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW